Haleon (NYSE:HLN) & Bio-Rad Laboratories (NYSE:BIO) Head-To-Head Survey

Bio-Rad Laboratories (NYSE:BIO) and Haleon (NYSE:HLN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Bio-Rad Laboratories and Haleon, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	1	2	3	0	2.33
Haleon	1	2	4	2	2.78

Bio-Rad Laboratories currently has a consensus price target of $358.50, suggesting a potential upside of 28.12%. Haleon has a consensus price target of $12.33, suggesting a potential upside of 23.93%. Given Bio-Rad Laboratories’ higher possible upside, equities research analysts plainly believe Bio-Rad Laboratories is more favorable than Haleon.

Insider and Institutional Ownership

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 6.7% of Haleon shares are owned by institutional investors. 17.1% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bio-Rad Laboratories and Haleon”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58 billion	2.92	$759.90 million	$27.91	10.03
Haleon	$14.54 billion	3.05	$2.20 billion	$0.39	25.50

Haleon has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Rad Laboratories and Haleon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	29.42%	3.86%	2.70%
Haleon	N/A	N/A	N/A

Volatility & Risk

Bio-Rad Laboratories has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Haleon has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Summary

Bio-Rad Laboratories beats Haleon on 8 of the 15 factors compared between the two stocks.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.